Lost Pregabalin Prescription: Controlled Drug Dilemma

Clinical Scenario

Margarita Carr, 42, a single mother working part-time at a supermarket, calls reporting she has lost her pregabalin for the second time in two months. She takes pregabalin 150mg twice daily for fibromyalgia and generalised anxiety. She is already experiencing withdrawal symptoms — shakiness, worsening anxiety, and intensified pain. Her first loss two months ago was attributed to a stolen handbag with a police report. She cares for her elderly mother and her 14-year-old son who is struggling at school.

What This Case Tests

Balancing prescribing safety responsibilities with patient welfare; assessing the legitimacy of a repeated controlled drug loss; managing pregabalin withdrawal risk; creating practical safeguards without being punitive; recognising the social complexity of a patient who is a single parent, carer, and chronic pain sufferer.

Common Mistakes Trainees Make

The two most critical mistakes in this case are: either automatically replacing the prescription without any safeguards (which ignores prescribing responsibilities for a controlled substance) or refusing to prescribe and dismissing the patient as drug-seeking (which risks dangerous withdrawal and ignores the legitimate clinical need and social context). A third common error is failing to explore the patient's chaotic life circumstances — single parenting, caring responsibilities, chronic pain, and shift work — which explain why medication loss is plausible without diversion.

The Consultation Challenge

Margarita is 42 years old and is calling because she has lost her pregabalin prescription — for the second time in two months. She has fibromyalgia, generalised anxiety disorder, and is on pregabalin 150mg twice daily. She is also a single mother, caring for her elderly mother, and working an unpredictable shift pattern. The previous loss was attributed to a verified crime (theft) and a replacement was issued with safety advice.

This case sits at the intersection of controlled drug prescribing, patient safety, professional duty, and empathy. Pregabalin is a Class C controlled substance with recognised misuse and diversion potential. Two lost prescriptions in two months triggers a legitimate prescribing concern — but the patient also has genuine chronic pain, documented medical conditions, and significant life stressors that could explain the losses.

The examiner is testing whether you can hold both realities simultaneously: maintaining prescribing safety without becoming adversarial, and showing empathy without being naive. This is one of the hardest balancing acts in the SCA.

Your immediate clinical priority is withdrawal risk. Abrupt pregabalin discontinuation can cause seizures, rebound anxiety, insomnia, and pain flares. If you decide not to issue a full replacement, you still need to manage withdrawal safely — a short emergency supply with daily or weekly dispensing may be the pragmatic solution.

The conversation must be non-accusatory but direct. You need to explore the circumstances of this loss, understand her storage systems, and discuss what would happen if a third loss occurred. Setting clear boundaries about future prescribing is essential — not as punishment, but as a transparent framework that protects both the patient and your professional responsibility.

Time check: Spend the first 3 minutes understanding the circumstances of the loss and assessing for withdrawal symptoms. By minute 5, make your prescribing decision and explain your reasoning transparently. Use minutes 6-9 for putting practical measures in place (weekly dispensing, secure storage plan, named pharmacy). Reserve the final 3 minutes for the longer-term medication review conversation and follow-up planning.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you explore the circumstances of the loss without accusation (what happened, when, has she reported it), screen for withdrawal symptoms (anxiety, tremor, sleep disturbance, pain flare), assess her current functional status, and review the pattern of prescribing. Critically, they look for whether you take a balanced approach — gathering information that could indicate either genuine loss or misuse without prejudging. You should also assess for signs of dependence beyond therapeutic use: dose escalation, running out early, obtaining from other sources.

Clinical Management and Medical Complexity: This is the highest-scoring domain. Examiners expect a structured approach: immediate withdrawal risk management (an emergency short supply if needed), a clear prescribing framework for the future (weekly dispensing at a named pharmacy, no further replacements without police report), and a plan for the longer-term medication review (is pregabalin still the best option for her fibromyalgia? Could she step down or switch?). Knowledge of controlled drug prescribing regulations, the risks of pregabalin misuse, and withdrawal management demonstrates clinical maturity.

Relating to Others: This is where most trainees either score very well or very poorly. Examiners assess whether you maintain a non-judgmental, partnership approach while still setting clear boundaries. The patient has genuine chronic pain and significant life stressors — dismissing her as "drug-seeking" is both clinically wrong and scores terribly. Equally, prescribing without any discussion of the pattern is naive. The winning approach is transparent honesty: "I believe you, and I want to help, but I also have a responsibility to prescribe safely — so let's work out a plan together."

Example Opening

Strong opening: "Hello Margarita, I can see you've called about your pregabalin. Before we get into that, how are you doing generally? I know you've got a lot on your plate."

This acknowledges her as a whole person before addressing the medication issue, which builds rapport and provides context.

When addressing the pattern: "I want to be completely open with you. This is the second time your pregabalin has gone missing in a short period, and as your doctor, I have a duty to prescribe controlled medicines safely. That doesn't mean I don't believe you — it means I need to put measures in place that protect you. Can we talk about what those might look like?"

This is transparent without being accusatory, and frames the safety measures as being for her benefit rather than a punishment.

Avoid: "I'm afraid we can't keep replacing controlled drugs — it flags on our system." (Hides behind administrative process rather than having an honest clinical conversation).

How This Appears in the SCA

Controlled drug dilemmas are high-value SCA cases testing your ability to balance prescribing governance with patient-centred care. Examiners assess whether you can make a nuanced clinical judgment rather than applying a rigid policy. This case also tests your awareness of social determinants of health — the patient's chaotic circumstances are central to understanding the clinical picture.

Key Statistic

Pregabalin was reclassified as a Schedule 3 controlled drug in the UK in April 2019 due to rising misuse. However, abrupt discontinuation carries genuine medical risk including seizures, and withdrawal management requires clinical supervision.

Relevant Guidelines

• NICE NG215: Medicines associated with dependence or withdrawal symptoms — includes pregabalin
• BNF guidance on pregabalin as a Schedule 3 controlled drug
• MHRA safety advice on pregabalin withdrawal risks.

Frequently Asked Questions

How should I approach a patient who repeatedly loses controlled medication?

Balance empathy with professional responsibility. Explore the circumstances non-judgmentally, assess for withdrawal risk, and make a clinical decision about whether to issue a replacement or emergency supply. Set clear boundaries for the future: weekly dispensing at a named pharmacy, secure storage advice, and transparency that further losses will require a different approach. Frame these as safety measures, not punishment. The examiner is assessing whether you can hold both realities — genuine need and prescribing concern — simultaneously.

What are the withdrawal risks from abrupt pregabalin discontinuation?

Pregabalin withdrawal can cause seizures (even in patients without epilepsy), rebound anxiety, insomnia, nausea, diarrhoea, and significant pain flares. Symptoms can begin within 24-48 hours of the last dose. Even if you have concerns about the pattern of losses, you should not leave the patient without any supply — an emergency 5-7 day prescription with daily or weekly pharmacy dispensing manages withdrawal safely while you put a longer-term plan in place.

What is the legal status of pregabalin and why does it matter?

Pregabalin was reclassified as a Class C controlled substance and Schedule 3 drug in April 2019 due to evidence of increasing misuse and diversion. This means prescribers have additional responsibilities around record-keeping, quantity limits, and monitoring for signs of misuse. Demonstrating awareness of this reclassification and its implications in the SCA shows strong Clinical Management knowledge.

How do I set prescribing boundaries without damaging the doctor-patient relationship?

Transparency is key. Explain your reasoning openly: "I have a professional responsibility to prescribe controlled medicines safely, and that means putting some structure around how you receive your medication." Frame practical measures (weekly dispensing, named pharmacy) as support rather than surveillance. Involve the patient in problem-solving: "What do you think would help prevent this happening again?" This collaborative approach maintains trust while establishing clear expectations.

Should I consider switching the patient away from pregabalin?

A longer-term medication review is appropriate and demonstrates proactive management. If fibromyalgia is the primary indication, alternatives include duloxetine or amitriptyline. If anxiety is the primary indication, an SSRI may be more appropriate for long-term management. However, this conversation should be separate from the crisis of the lost prescription — raising it now may feel punitive. Schedule a dedicated review appointment and frame it as optimising her treatment, not removing her medication.